In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Innovent Biologics, Inc.

http://www.innoventbio.com/en/

Latest From Innovent Biologics, Inc.

H1 Winners And Laggards In China's Sizzling Home-Grown IO market

Four latecomers including Akeso and Henlius managed to record a combined $101m in immuno-oncology drug sales in China in the first half, while market leaders such as BeiGene and Innovent saw mixed results as competition between domestically-developed rivals continues to heat up.

China ImmunoOncology

BeiGene Head of R&D Lai Wang On Going Global

The Chinese company's R&D leader discusses the US regulatory environment for Chinese-made drugs and implications for the cancer-focused company.

Regulation Drug Approval Standards

BeiGene Head of R&D Lai Wang On Going Global

The Chinese company's R&D leader talked to Scrip about the US regulatory environment for Chinese-made drugs and implications for the cancer-focused company.

Business Strategies Clinical Trials

Location, Location, Location: Will Sorrento’s China-Only NSCLC Data Fly With US FDA?

Sorrento plans to meet with the US FDA regarding abivertinib, but the agency’s tough stance on drug approvals based on single-country studies could thwart the company’s efforts.

FDA China
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Other Names / Subsidiaries
    • Innovent Biologics (Suzhou) Co., Ltd.
UsernamePublicRestriction

Register